Neurocrine Biosciences Study Shows INGREZZA Improves Quality of Life for Tardive Dyskinesia Patients
Event summary
- Neurocrine Biosciences published KINECT-PRO study results showing INGREZZA improved patient-reported quality of life and functionality in tardive dyskinesia patients.
- 58% of patients achieved symptomatic remission after 24 weeks of treatment with INGREZZA.
- Improvements were observed regardless of underlying psychiatric diagnosis or baseline movement severity.
- The study used multiple validated patient-reported outcomes, including the Tardive Dyskinesia Impact Scale (TDIS).
- Safety and tolerability of INGREZZA were consistent with its known profile.
The big picture
Neurocrine Biosciences' KINECT-PRO study reinforces the strategic value of patient-reported outcomes in neurological drug development. The results position INGREZZA as a differentiated treatment option for tardive dyskinesia, potentially expanding its market reach beyond movement severity improvements to encompass broader quality-of-life benefits. This aligns with industry trends emphasizing holistic patient care metrics in psychiatric and neurological conditions.
What we're watching
- Market Differentiation
- How INGREZZA's demonstrated improvements in quality of life will position it against competitors in the tardive dyskinesia market.
- Regulatory Strategy
- Whether Neurocrine Biosciences will leverage these results to expand INGREZZA's approved indications or dosing regimens.
- Commercialization Impact
- The pace at which payors and prescribers adopt INGREZZA based on these patient-reported outcome data.